Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bayer A G Ord (BAYZF)

Bayer A G Ord (BAYZF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 20.57
  • Price/Book 5.23
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.7300 +19.84%
on 01/12/26
55.1050 -0.54%
on 02/09/26
+9.4800 (+20.92%)
since 01/09/26
3-Month
31.2290 +75.49%
on 11/20/25
55.1050 -0.54%
on 02/09/26
+23.0850 (+72.78%)
since 11/11/25
52-Week
20.9900 +161.10%
on 04/09/25
55.1050 -0.54%
on 02/09/26
+33.3630 (+155.60%)
since 02/11/25

Most Recent Stories

More News
Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month

This February, the brand continues its See Your Risks initiative by challenging denial and bringing unseen heart health risk factors into view.

BAYRY : 13.8100 (+1.32%)
BAYZF : 54.8050 (-0.08%)
BAYN : 0.0100 (unch)
Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo

In OCEANIC-STROKE, patients who received asundexian after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack were significantly less likely to suffer a secondary stroke compared...

BAYRY : 13.8100 (+1.32%)
BAYZF : 54.8050 (-0.08%)
Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign

‘Highlights REAL’ aims to spark vital conversations about advanced prostate cancer and educate about the importance of treatment management

BAYRY : 13.8100 (+1.32%)
BAYZF : 54.8050 (-0.08%)
BAYN : 0.0100 (unch)
Bayer Investing More Than $45M CAD to Build World-Class Canola Research and Development Facility in Canada

Bayer Crop Science today announced an unprecedented $45+ million CAD investment to strengthen Canada’s leadership in canola innovation by establishing a cutting-edge canola innovation centre. Located...

BAYRY : 13.8100 (+1.32%)
BAYZF : 54.8050 (-0.08%)
BAYN : 0.0100 (unch)
Bayer to Present Results From Phase III OCEANIC-STROKE Study of Asundexian in Secondary Stroke Prevention

Findings from OCEANIC-STROKE, including the main results and a prespecified subgroup analysis, will be presented for the first time during two late-breaking sessions at the International Stroke Conference...

BAYRY : 13.8100 (+1.32%)
BAYZF : 54.8050 (-0.08%)
Bayer and Vanderbilt University Medical Center to Advance Treatments for Cardiovascular and Kidney Diseases

Not intended for UK Media Collaboration spans across various indications with an initial focus on cardiovascular and kidney diseases, addressing areas of significant...

BAYRY : 13.8100 (+1.32%)
BAYZF : 54.8050 (-0.08%)
BAYN : 0.0100 (unch)
Bayer Accelerates Pharma Growth on High-Value Portfolio

Bayer is successfully executing on an ambitious growth strategy Five pivotal approvals worldwide in 2025 underscore a landmark year of strategic execution Bayer will...

BAYRY : 13.8100 (+1.32%)
BAYZF : 54.8050 (-0.08%)
BAYN : 0.0100 (unch)
Actress and Menopause Advocate Gabrielle Union-Wade Partners with Bayer in the Lynkuet® (elinzanetant) ‘Life Doesn’t Stop for a Hot Flash’ Campaign for Moderate to Severe Hot Flashes Due to Menopause

In the ‘Life Doesn’t Stop for a Hot Flash’ campaign, Gabrielle Union-Wade and Bayer partner together to help raise awareness about an available treatment option for moderate to severe hot flashes...

BAYRY : 13.8100 (+1.32%)
BAYZF : 54.8050 (-0.08%)
BAYN : 0.0100 (unch)
Bayer to Expand Into Molecular Imaging With Acquisition of Innovative Pan-Amyloid Radiotracers From Attralus

Not intended for UK Media Bayer bolsters development portfolio by acquisition of two investigational imaging agents (AT-01 and AT-05) from Attralus, Inc. to advance diagnosis...

BAYRY : 13.8100 (+1.32%)
BAYZF : 54.8050 (-0.08%)
BAYN : 0.0100 (unch)
Bayer and Soufflé Therapeutics Announce Strategic Collaboration to Advance Cell-Specific Heart-Targeted siRNA Therapy

Not intended for UK Media Collaboration focuses on developing potential best in class siRNA-based treatment for a form of dilated cardiomyopathy Bayer...

BAYRY : 13.8100 (+1.32%)
BAYZF : 54.8050 (-0.08%)
BAYN : 0.0100 (unch)

Business Summary

Bayer AG is an international research-based company active in life sciences, polymers, and chemicals. Bayer's operating units include health-care products, material sciences, and crop sciences. Bayer's over-the-counter health-care product division is the third-largest in the world. HealthCare subgroup...

See More

Key Turning Points

3rd Resistance Point 54.8050
2nd Resistance Point 54.8050
1st Resistance Point 54.8050
Last Price 54.8050
1st Support Level 54.8050
2nd Support Level 54.8050
3rd Support Level 54.8050

See More

52-Week High 55.1050
Last Price 54.8050
Fibonacci 61.8% 42.0731
Fibonacci 50% 38.0475
Fibonacci 38.2% 34.0219
52-Week Low 20.9900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar